A novel imaging biomarker for survival prediction in EGFR-mutated NSCLC patients treated with TKI
A. Collin, V. Groza, L. Missenard, F. Chomy, T. Colin, J. Palussiere, O. Saut
This study develops an imaging biomarker based on tumor heterogeneity evolution to predict survival in EGFR-mutated NSCLC patients treated with TKI, showing a statistically significant correlation with overall survival.
bioRxiv · Jun 24, 2019 · PreprintCancer Biology